Mirjana Efremova speaks to Megan Bryant, Journal Development Editor for Colorectal Cancer at the 4th International Cancer Conference at the CRICK Institute about her research into how colorectal cells adapt and change through plasticity.
{"title":"The role of colorectal cancer plasticity in metastasis and treatment: an interview with Mirjana Efremova","authors":"Mirjana Efremova","doi":"10.2217/crc-2023-0015","DOIUrl":"https://doi.org/10.2217/crc-2023-0015","url":null,"abstract":"Mirjana Efremova speaks to Megan Bryant, Journal Development Editor for Colorectal Cancer at the 4th International Cancer Conference at the CRICK Institute about her research into how colorectal cells adapt and change through plasticity.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"7 6","pages":""},"PeriodicalIF":4.2,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139015222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: To evaluate the association between the diameter of the superior rectal vein (dSRV) and prognosis in patients with locally advanced rectal cancer (LARC). Methods: This study included 420 LARC patients. Kaplan-Meier survival analysis and Cox regression models were used for determining the relationship between superior rectal vein diameter and survival. Results: Patients whose dSRV >3.60 mm had better 3 years disease-free survival (85.50 vs 64.2%, p < 0.001) and overall survival (91.90 vs 82.20%, p = 0.005). The multivariate Cox regression analysis showed that the dSRV was an independent prognostic factor for survival. Conclusion: The dSRV measurement is valuable in predicting the prognosis of patients with LARC, and the prognosis of patients with a smaller dSRV seems to be poor.
目的:探讨局部晚期直肠癌(LARC)患者直肠上静脉(dSRV)直径与预后的关系。方法:本研究纳入420例LARC患者。采用Kaplan-Meier生存分析和Cox回归模型确定直肠上静脉直径与生存的关系。结果:dSRV >3.60 mm的患者3年无病生存率更高(85.50 vs 64.2%， p <0.001)和总生存率(91.90 vs 82.20%， p = 0.005)。多因素Cox回归分析显示，dSRV是影响生存的独立预后因素。结论:dSRV测量对预测LARC患者的预后有一定的价值，dSRV较小的患者预后较差。
{"title":"Prognostic significance of the diameter of superior rectal vein for locally advanced rectal cancer","authors":"Yafang Hong, Anchuan Li, Runfan Chen, Benhua Xu","doi":"10.2217/crc-2023-0004","DOIUrl":"https://doi.org/10.2217/crc-2023-0004","url":null,"abstract":"Aim: To evaluate the association between the diameter of the superior rectal vein (dSRV) and prognosis in patients with locally advanced rectal cancer (LARC). Methods: This study included 420 LARC patients. Kaplan-Meier survival analysis and Cox regression models were used for determining the relationship between superior rectal vein diameter and survival. Results: Patients whose dSRV >3.60 mm had better 3 years disease-free survival (85.50 vs 64.2%, p < 0.001) and overall survival (91.90 vs 82.20%, p = 0.005). The multivariate Cox regression analysis showed that the dSRV was an independent prognostic factor for survival. Conclusion: The dSRV measurement is valuable in predicting the prognosis of patients with LARC, and the prognosis of patients with a smaller dSRV seems to be poor.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" 13","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135286124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Wyrwicz, J. Taieb, T. Price, J. Bachet, M. Karthaus, L. Vidot, Bénédicte Chevallier, T. Reisländer, L. Weiss, V. Heinemann
Background: QLQ-C30 Global Health Status (GHS) and Eastern Cooperative Oncology Group performance status (ECOG PS) data from PRECONNECT and TALLISUR studies were pooled. Materials & methods: Association between changes in ECOG PS and QLQ-C30 GHS in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) was evaluated using Cox regression analysis. Results: 1100 patients were included. There was no clinically relevant change from baseline in QLQ-C30 GHS score through cycle 7. 63.0% of patients maintained/improved ECOG PS. The presence of liver metastasis increased the risk of QLQ-C30 GHS score/ECOG PS deterioration. The association between time to ECOG PS deterioration and change in QLQ-C30 GHS score over time was significant (HR 1.71 [95% CI: 1.4, 2.2]). Conclusion: ECOG PS and QLQ-C30 GHS scores were maintained during FTD/TPI treatment, and these measures were associated. Factors that increased the risk of deterioration included the presence of liver/lung metastasis, younger age and shorter time since first metastasis. Clinical Trial Registration: PRECONNECT (EudraCT Number: 2016-002311-18 ) and TALLISUR (EudraCT-Number: 2017-000292-83 ).
{"title":"Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies","authors":"L. Wyrwicz, J. Taieb, T. Price, J. Bachet, M. Karthaus, L. Vidot, Bénédicte Chevallier, T. Reisländer, L. Weiss, V. Heinemann","doi":"10.2217/crc-2022-0013","DOIUrl":"https://doi.org/10.2217/crc-2022-0013","url":null,"abstract":"Background: QLQ-C30 Global Health Status (GHS) and Eastern Cooperative Oncology Group performance status (ECOG PS) data from PRECONNECT and TALLISUR studies were pooled. Materials & methods: Association between changes in ECOG PS and QLQ-C30 GHS in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) was evaluated using Cox regression analysis. Results: 1100 patients were included. There was no clinically relevant change from baseline in QLQ-C30 GHS score through cycle 7. 63.0% of patients maintained/improved ECOG PS. The presence of liver metastasis increased the risk of QLQ-C30 GHS score/ECOG PS deterioration. The association between time to ECOG PS deterioration and change in QLQ-C30 GHS score over time was significant (HR 1.71 [95% CI: 1.4, 2.2]). Conclusion: ECOG PS and QLQ-C30 GHS scores were maintained during FTD/TPI treatment, and these measures were associated. Factors that increased the risk of deterioration included the presence of liver/lung metastasis, younger age and shorter time since first metastasis. Clinical Trial Registration: PRECONNECT (EudraCT Number: 2016-002311-18 ) and TALLISUR (EudraCT-Number: 2017-000292-83 ).","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"1 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41902939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jonathan T Pham, W. Wong, Vonn Walter, J. Scow, M. Deutsch, A. Kulaylat
Aim: This study aims to examine trends in incidence and mortality of colorectal cancer (CRC) using a state-wide registry, focusing on race, age, and rurality. Methods: From 1990 to 2019, CRC age-adjusted incidence and mortality were examined through the Pennsylvania Cancer Registry using Joinpoint Regression to model average annual percent changes (AAPC). Results: In Pennsylvania, there was a decline in incidence (AAPC -1.7) and mortality (AAPC -2.5), consistent regardless of race or cancer stage, with an inflection in the 2000s demonstrating greater rate of decrease. Conversely, patients under 50 saw rising CRC incidence (AAPC 1.8). Rural counties showed higher mortality than urban counties. Conclusion: Across Pennsylvania, the incidence and mortality rates of CRC have decreased over the past three decades, apart from patients under 50.
{"title":"Colorectal cancer incidence and mortality: trends from the Pennsylvania Cancer Registry across three decades","authors":"Jonathan T Pham, W. Wong, Vonn Walter, J. Scow, M. Deutsch, A. Kulaylat","doi":"10.2217/crc-2022-0011","DOIUrl":"https://doi.org/10.2217/crc-2022-0011","url":null,"abstract":"Aim: This study aims to examine trends in incidence and mortality of colorectal cancer (CRC) using a state-wide registry, focusing on race, age, and rurality. Methods: From 1990 to 2019, CRC age-adjusted incidence and mortality were examined through the Pennsylvania Cancer Registry using Joinpoint Regression to model average annual percent changes (AAPC). Results: In Pennsylvania, there was a decline in incidence (AAPC -1.7) and mortality (AAPC -2.5), consistent regardless of race or cancer stage, with an inflection in the 2000s demonstrating greater rate of decrease. Conversely, patients under 50 saw rising CRC incidence (AAPC 1.8). Rural counties showed higher mortality than urban counties. Conclusion: Across Pennsylvania, the incidence and mortality rates of CRC have decreased over the past three decades, apart from patients under 50.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2023-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45602422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Khandu Wadhonkar, Neha Singh, F. Heralde, S. P. Parihar, N. Hirani, M. Baig
Colorectal cancer is one of the leading causes of death worldwide. Its incidence and mortality have significantly increased during the past few years. Colorectal cancer cells cross-talk with other cells through exosomes in their tumor microenvironment. The miRNAs containing exosomes are responsible for tumor growth, invasion, and metastasis. Multiple studies have shown that exosomal miRNAs are key players in the crosstalk between cancerous, immune, and stromal cells during colorectal cancer development. They help in the establishment of the tumorigenic microenvironment by reprogramming macrophages towards a pro-tumorigenic phenotype. In this review, we discussed various exosomal miRNAs derived both from colorectal cancer cells and macrophages that promote or inhibit cancer aggression. We also discussed various miRNA-based therapeutic approaches to inhibit cancer progression.
{"title":"Exosome-derived miRNAs regulate macrophage-colorectal cancer cell cross-talk during aggressive tumor development","authors":"Khandu Wadhonkar, Neha Singh, F. Heralde, S. P. Parihar, N. Hirani, M. Baig","doi":"10.2217/crc-2022-0012","DOIUrl":"https://doi.org/10.2217/crc-2022-0012","url":null,"abstract":"Colorectal cancer is one of the leading causes of death worldwide. Its incidence and mortality have significantly increased during the past few years. Colorectal cancer cells cross-talk with other cells through exosomes in their tumor microenvironment. The miRNAs containing exosomes are responsible for tumor growth, invasion, and metastasis. Multiple studies have shown that exosomal miRNAs are key players in the crosstalk between cancerous, immune, and stromal cells during colorectal cancer development. They help in the establishment of the tumorigenic microenvironment by reprogramming macrophages towards a pro-tumorigenic phenotype. In this review, we discussed various exosomal miRNAs derived both from colorectal cancer cells and macrophages that promote or inhibit cancer aggression. We also discussed various miRNA-based therapeutic approaches to inhibit cancer progression.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47345482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Babajanyan, Megan Pollack, Sarah Castelo, A. Kavati, T. Bekaii-Saab
There is limited evidence-based guidance regarding treatment sequencing and outcomes following regorafenib in patients with refractory metastatic colorectal cancer (mCRC). A targeted literature review was conducted to identify studies with clinical outcomes associated with regorafenib therapy and subsequent treatment following regorafenib therapy. The median overall survival range of the nine studies with sequenced-based survival data was 2.1–19.3 months for regorafenib prior to subsequent therapy in refractory mCRC. Safety outcomes in patients treated with regorafenib prior to other therapies in mCRC were generally comparable to reported adverse events in clinical trials for subsequent agents. Data from this review demonstrate a potential correlation between survival and the use of regorafenib prior to subsequent chemotherapy or targeted therapy in patients with refractory mCRC.
{"title":"Sequenced treatment after regorafenib and survival in metastatic colorectal cancer: a qualitative clinical review","authors":"S. Babajanyan, Megan Pollack, Sarah Castelo, A. Kavati, T. Bekaii-Saab","doi":"10.2217/crc-2022-0006","DOIUrl":"https://doi.org/10.2217/crc-2022-0006","url":null,"abstract":"There is limited evidence-based guidance regarding treatment sequencing and outcomes following regorafenib in patients with refractory metastatic colorectal cancer (mCRC). A targeted literature review was conducted to identify studies with clinical outcomes associated with regorafenib therapy and subsequent treatment following regorafenib therapy. The median overall survival range of the nine studies with sequenced-based survival data was 2.1–19.3 months for regorafenib prior to subsequent therapy in refractory mCRC. Safety outcomes in patients treated with regorafenib prior to other therapies in mCRC were generally comparable to reported adverse events in clinical trials for subsequent agents. Data from this review demonstrate a potential correlation between survival and the use of regorafenib prior to subsequent chemotherapy or targeted therapy in patients with refractory mCRC.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"1 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44233891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-07DOI: 10.5772/intechopen.94868
T. Teneva, A. Zlatarov, R. Grigorov
In a chapter about rectal cancer there is content about rectal anatomy in relation to magnet-resonanse imaging and TME- surgery (total mesorectal excision). Secondly there is content about imaging methods used in diagnosis and follow-up of rectal cancer. Very important topic is concerning the novel imaging strategies in surgical and radiotherapy planning in the era of individual oncologic approach to the patient. At last there is detailed desctiption and metaanalysis of imaging strategies concerning neoadjuvant and adjuvant radiotherapy and chemotherapy for rectal cancer patients. All imaging markers correspond to substantial oncologic parameters such as survival rates. The connecting bridge is magnet-resonance imaging.
{"title":"Role of Magnetic Resonance Imaging in Patients with Rectal Cancer","authors":"T. Teneva, A. Zlatarov, R. Grigorov","doi":"10.5772/intechopen.94868","DOIUrl":"https://doi.org/10.5772/intechopen.94868","url":null,"abstract":"In a chapter about rectal cancer there is content about rectal anatomy in relation to magnet-resonanse imaging and TME- surgery (total mesorectal excision). Secondly there is content about imaging methods used in diagnosis and follow-up of rectal cancer. Very important topic is concerning the novel imaging strategies in surgical and radiotherapy planning in the era of individual oncologic approach to the patient. At last there is detailed desctiption and metaanalysis of imaging strategies concerning neoadjuvant and adjuvant radiotherapy and chemotherapy for rectal cancer patients. All imaging markers correspond to substantial oncologic parameters such as survival rates. The connecting bridge is magnet-resonance imaging.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2020-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48255327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer and other solid tumors: is it truly disease-agnostic?","authors":"I. Sahin","doi":"10.2217/crc-2020-0020","DOIUrl":"https://doi.org/10.2217/crc-2020-0020","url":null,"abstract":"","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47839532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-16DOI: 10.5772/INTECHOPEN.93978
A. Pissarra, C. Abreu, A. Mansinho, Ana Lúcia Costa, S. Dâmaso, S. Lobo-Martins, Marta Martins, L. Costa
Colorectal cancer (CRC) is one of the most frequent and lethal cancer types worldwide. While surgery with chemotherapy and radiotherapy remains the only curative approach for localized CRC, for metastatic disease the therapeutic landscape has significantly evolved over the last years. Development and approval of novel targeted therapies, such as monoclonal antibodies against EGFR and VEGF, have significantly increased the median survival of patients with metastatic disease, with some trials reporting a benefit over 40 months. Increasing accessibility of high throughput sequencing has unraveled several new therapeutic targets. Actionable alterations, such as HER2 overexpression, BRAF mutations, and NTRK fusions, are currently available in metastatic disease, providing significant therapeutic opportunities for these patients, while new emerging agents, as immune checkpoint inhibitors, promise better treatment options in the near future. In this chapter, an overview of established and future CRC targeted therapies in the clinical setting is provided, as well as their mechanism of action, limitations, and future applicability.
{"title":"Landscape of Current Targeted Therapies for Advanced Colorectal Cancer","authors":"A. Pissarra, C. Abreu, A. Mansinho, Ana Lúcia Costa, S. Dâmaso, S. Lobo-Martins, Marta Martins, L. Costa","doi":"10.5772/INTECHOPEN.93978","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.93978","url":null,"abstract":"Colorectal cancer (CRC) is one of the most frequent and lethal cancer types worldwide. While surgery with chemotherapy and radiotherapy remains the only curative approach for localized CRC, for metastatic disease the therapeutic landscape has significantly evolved over the last years. Development and approval of novel targeted therapies, such as monoclonal antibodies against EGFR and VEGF, have significantly increased the median survival of patients with metastatic disease, with some trials reporting a benefit over 40 months. Increasing accessibility of high throughput sequencing has unraveled several new therapeutic targets. Actionable alterations, such as HER2 overexpression, BRAF mutations, and NTRK fusions, are currently available in metastatic disease, providing significant therapeutic opportunities for these patients, while new emerging agents, as immune checkpoint inhibitors, promise better treatment options in the near future. In this chapter, an overview of established and future CRC targeted therapies in the clinical setting is provided, as well as their mechanism of action, limitations, and future applicability.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"1 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2020-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42370281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：